ATLANTA, May 16, 2014 /PRNewswire/ -- Surgical Infection Society members attended an opening day continuing medical education (CME) lunch symposium sponsored by IrriMax Corporation, the makers of IRRISEPT, the first and only FDA-cleared cleansing and debridement system containing 0.05% Chlorhexidine Gluconate (CHG) for irrigation.
A three member panel of distinguished surgeons, Dr. Donald Fry, Dr. Nick Namias and Dr. Kamal Itani presented a CME/CE accredited program entitled “Local Measures to Prevent SSI”.
Dr. Itani reviewed clinical evidence related to pre-operative skin preparation. Dr. Namias addressed the clinical evidence surrounding the merits of primary closure vs. delayed primary closure. Dr. Fry reviewed studies regarding topical use of antibiotics in surgical wounds and described a planned multi-center trial on surgical irrigation with 0.05% CHG. The panel presentation will be published in Surgical Infections, the official journal of the Surgical Infection Society (SIS).
IrriMax was excited to sponsor this important panel discussion. The company’s main corporate goal is to help treat and prevent infections, help improve patient outcomes and drive positive impact to healthcare economics regarding surgical infections.
“We believe it’s important to work closely with key professional societies, such as SIS. With our focus on reducing Surgical Site Infections, it is critical that we engage with the experts in this field, to collaborate and learn from them,” said Gareth Clarke, CEO of IrriMax Corporation.
The company’s VP Clinical Affairs, Carolyn Twomey, stated, “SIS members represent those surgeons who are on the cutting edge of research, technology and education regarding surgical infections and improving surgical patient outcomes.” She went on to say, “We are getting ready to launch a multi-center, randomized, controlled, clinical trial with IRRISEPT. Corporately, we are driving a rigorous, world-class clinical program and it’s imperative to support and partner in these events. Most, if not all, of the principal investigators in our trial are members of SIS and many are attending this conference.”
IRRIMAX CORPORATION
IrriMax® Corporation develops and markets cleansing, debridement and irrigation solutions using a patented, innovative delivery method. Continual innovation and ongoing clinical research guide the development of IrriMax products. For more information visit www.irrisept.com.
CONTACT
IrriMax Corporation
Corporate Headquarters 770-807-3355
kellyh@irrisept.com
SOURCE IrriMax Corporation
Help employers find you! Check out all the jobs and post your resume.
